Wealth Club
Subtitle
Blog
FDA accepts Regeneron's application for Eylea for diabetic retinopathy, action date May 13, 2019
|
|
The FDA accepts for review Regeneron Pharmaceuticals' (NASDAQ:REGN) marketing application seeking approval to use EYLEA (aflibercept) to treat patients with diabetic retinopathy. The agency's action date is May 13, 2019.
Related ticker: (OTCPK:BAYRY)
Source: https://seekingalpha.com/news/3389917-fda-accepts-regenerons-application-eylea-diabetic-retinopathy-action-date-may-13-2019?source=feed_news_all
Categories: None
Post a Comment
Oops!
The words you entered did not match the given text. Please try again.
Oops!
Oops, you forgot something.